Loading clinical trials...

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

A Randomized, Subject and Evaluator Blinded, Matched Pairs, Pilot Study to Evaluate the Safety and Efficacy of DMSB01 According to the Number of Injections in Subjects With Crow's Feet Lines Compared to Control Device

NCT06402058•Samyang Biopharmaceuticals Corporation

View on ClinicalTrials.gov

Summary

The objective of this Pilot Study is to verify the safety and efficacy of DMSB01 in the temporary improvement of Crow's Feet Lines

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Among those who desire improvement in both sides of the crow's feet and have a Crow's Feet Grading Scale (CFGS) score of 2 or higher for both relaxed and maximum smile conditions
•2. Individuals who have consented to abstain from any other dermatological procedures or treatments, including treatments for wrinkle reduction in the facial area, during the duration of this study

Exclusion Criteria

•1. Individuals with abnormal findings in visual-related tests (visual acuity test, Confrontational visual fields test, ocular motility test), specifically those with low vision (best-corrected visual acuity of 0.3 or less in the better eye).
•2. Individuals who need to take anticoagulants from 2 weeks before the application of the investigational medical device to 2 weeks after the final application (with the exception of low dosage aspirin 100mg (up to a maximum of 300mg/day))
•3. Individuals who need to take Vitamin E preparations, NSAIDs, or collagen preparations from 1 week before the application of the investigational medical device to 1 week after the final application.
•4. History of bleeding disorder in past or present

Key Dates

Start Date

June 10, 2024

Primary Completion Date

January 31, 2025

Completion Date

April 30, 2025

Last Updated

May 13, 2024

Enrollment

ESTIMATED participants

Conditions

Crow's Feet Lines

Interventions

DMSB01

DEVICE

Rejuran®

DEVICE

Contacts

Gyeongsoon Kim

CONTACT

+82-2-2157-9851 gyeongsoon.kim@samyang.com

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

NCT03408236

Crow's Feet Lines

View study

COMPLETEDPHASE3

BOTOX® in the Treatment of Crow's Feet Lines in Japan

NCT01797081

Lateral Canthus RhytidesCrow's Feet Lines

View study

COMPLETEDPHASE4

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

Inclusion Criteria

Exclusion Criteria

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

BOTOX® in the Treatment of Crow's Feet Lines in Japan

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

BOTOX® in the Treatment of Upper Facial Lines in Japan

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines